February 28, 2023
Factor Bioscience Announces Publication of Preclinical Results of Aerosolized mRNA For the Treatment of Pneumonia
-mRNA encoding immunomodulatory proteins IκBα-SR and SOD3 ameliorated symptoms in bacterial pneumonia model -Factor is investigating nebulized mRNA formulations for other therapeutic indications and next-generation vaccine applications CAMBRIDGE, Mass., February 28, 2023 /PRNewswire/ — Factor Bioscience Inc. (“Factor”), a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced the results of preclinical testing of […]
February 22, 2023
Eterna Therapeutics Enters Into Option and License Agreement With Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
CAMBRIDGE, MASS. – February 22, 2023 – Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna”), a preclinical-stage biotechnology company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Lineage Cell Therapeutics, Inc. (“Lineage”) for the development of novel induced hypoimmune […]
January 4, 2023
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announced the appointment of Matt Angel, Ph.D. as Chief Executive Officer (“CEO”) and President. Dr. Angel has served as Interim CEO and President of Eterna since […]
May 16, 2022
Factor Bioscience to Deliver Four Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
-Factor to reveal mRNA-based iPS cell-derived macrophages for solid-tumor targeting, allogeneic iPS cell-derived cytotoxic lymphocytes, and advanced targeted insertion technologies CAMBRIDGE, Mass., May 16, 2022 /PRNewswire/ — Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies, announced its participation in the American Society of Gene & Cell Therapy (ASGCT) 25th Annual […]
January 13, 2022
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) — Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announces that 18 new patents were issued and 17 new patent applications were filed in 2021. The intellectual property is owned by Factor Bioscience (“Factor”) and exclusively licensed to Brooklyn for various fields of therapeutic use. The newly-issued patents encompass those covering the Company’s mRNA-based cellular reprogramming and gene editing technology, as well as nucleic acid delivery using Brooklyn’s ToRNAdo™ lipid nanoparticle technology (LNP).
October 25, 2021
Factor Bioscience Joins Strategic Partner Brooklyn ImmunoTherapeutics to Ring the Nasdaq Closing Bell
CAMBRIDGE, Mass., Oct. 25, 2021 — The executive leadership of Factor Bioscience Inc., a Cambridge-based biotechnology company focused on developing mRNA and cell-engineering technologies joined the leadership of Factor’s strategic partner, Brooklyn ImmunoTherapeutics (Nasdaq: BTX) today at the Nasdaq MarketSite in Times Square, New York, for the ringing of the Nasdaq closing bell by Brooklyn’s President and CEO, Howard J. Federoff, M.D., Ph.D. Factor Bioscience was represented by Co-Founder, Chairman, and CEO, Matt Angel, Ph.D., and Co-Founder and Chief Technology Officer, Christopher Rohde, Ph.D., while the Brooklyn team included Jay Sial, Chief Administrative Officer, Roger Sidhu, M.D., Chief Medical Officer, Ron Guido, M.S., M.S. Pharm. Med., Chief Development Officer, and Lynn Sadowski-Mason, M.S., EVP Clinical Operations.
For media inquiries and interview requests, please contact:
Dirk Knemeyer
info@factorbio.com